Xu Yanping, Chen Luyi, Liu Weili, Chen Liying
Department of General Practice, Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou 310016, China.
Zhejiang Da Xue Xue Bao Yi Xue Ban. 2025 Jan 25;54(1):90-98. doi: 10.3724/zdxbyxb-2024-0249.
Inflammaging is a process of cellular dysfunction associated with chronic inflammation, which plays a significant role in the onset and progression of liver diseases. Research on its mechanisms has become a hotspot. In viral hepatitis, inflammaging primarily involve oxidative stress, cell apoptosis and necrosis, as well as gut microbiota dysbiosis. In non-alcoholic fatty liver disease, inflammaging is more complex, involving insulin resistance, fat deposition, lipid metabolism disorders, gut microbiota dysbiosis, and abnormalities in NAD metabolism. In liver tumors, inflammaging is characterized by weakening of tumor suppressive mechanisms, remodeling of the liver microenvironment, metabolic reprogramming, and enhanced immune evasion. Therapeutic strategies targeting inflammaging have been developing recently, and antioxidant therapy, metabolic disorder improvement, and immunotherapy are emerging as important interventions for liver diseases. This review focuses on the mechanisms of inflammaging in liver diseases, aiming to provide novel insights for the prevention and treatment of liver diseases.
炎症衰老(inflammaging)是一种与慢性炎症相关的细胞功能障碍过程,在肝脏疾病的发生和发展中起重要作用。对其机制的研究已成为一个热点。在病毒性肝炎中,炎症衰老主要涉及氧化应激、细胞凋亡和坏死,以及肠道微生物群失调。在非酒精性脂肪性肝病中,炎症衰老更为复杂,涉及胰岛素抵抗、脂肪沉积、脂质代谢紊乱、肠道微生物群失调以及NAD代谢异常。在肝肿瘤中,炎症衰老的特征是肿瘤抑制机制减弱、肝脏微环境重塑、代谢重编程和免疫逃逸增强。针对炎症衰老的治疗策略最近一直在发展,抗氧化治疗、改善代谢紊乱和免疫治疗正成为肝脏疾病的重要干预措施。本综述重点关注肝脏疾病中炎症衰老的机制,旨在为肝脏疾病的预防和治疗提供新的见解。